Mango Medical
Product & Competitive Intelligence
Automates surgical planning for orthopedic procedures from CT scans using agentic AI.
Company Overview
Builds an agentic AI planning platform that processes CT scans to automate and personalize preoperative planning for orthopedic surgeries, starting with shoulder arthroplasty.
Competitive Advantage & Moat
Product Roadmap & Public Announcements
Mango Medical has publicly indicated an initial product focus on instant, AI-driven surgical planning for shoulder arthroplasty via API, with active pursuit of FDA 510(k) clearance. Their YC profile highlights an 8-figure letter of intent from a leading orthopedic company, signaling near-term commercial deployment. They have publicly reported surpassing $500K ARR before Demo Day. Expansion to additional joint replacement procedures (hip, knee) and acute fracture planning is implied by company positioning and market messaging.
Signals & Private Analysis
Job postings and LinkedIn activity suggest investment in deep learning engineers specializing in 3D medical image segmentation and mesh reconstruction, pointing toward building out a full agentic pipeline that goes beyond static planning into intraoperative guidance. GitHub and conference signals hint at research into vision-language models for collaborative surgical action planning. The 8-figure LOI likely comes with co-development or data-sharing terms that would give Mango Medical a proprietary training data advantage. Expansion into spine and deformity correction is a logical next step given the underlying technology's generalizability. The company was originally founded in Freising, Germany before relocating to San Francisco for YC.
Product Roadmap Priorities
Automated 3D bone segmentation and anatomical landmark detection from CT scans to generate patient-specific surgical plans in seconds.
The AI automatically turns a raw CT scan into a precise 3D bone model and identifies key anatomical landmarks, so surgeons get a ready-made surgical blueprint instead of spending hours doing it manually.
It's like having a master sculptor who can look at a block of marble (your CT scan) and instantly see the statue inside it — except this sculptor also tells the surgeon exactly which chisel to use and where to cut.
Agentic AI surgical planning that autonomously selects optimal implant size, position, and orientation based on patient anatomy and surgical goals.
The AI acts like a virtual surgical resident that studies the patient's bone structure and automatically recommends the best implant and exactly where to place it, so the surgeon can review and approve rather than build the plan from scratch.
It's like having a master tailor who doesn't just measure you — they also pick the perfect fabric, cut the pattern, and pin everything in place before you even sit down for a fitting.
Predictive analytics and outcome modeling that forecasts post-surgical biomechanical performance and complication risk to guide plan selection.
The AI predicts how well a patient's joint will function after surgery and flags potential complications before the operation even happens, helping surgeons pick the safest and most effective plan.
It's like a weather forecast for your surgery — instead of just telling you to bring an umbrella, it shows you exactly which route has the least chance of rain and the smoothest road.
Company Overview
Key Team Members
- Adrian Kilian, Co-Founder & CEO
- Jorge Padilla Pérez, Co-Founder
Founder Force Multiplier
Mango Medical combines Adrian Kilian's background as a dentist, maxillofacial surgery researcher, and Stanford GSB Ignite alumnus with Jorge Padilla Pérez's deep learning and medical imaging engineering expertise, along with an early 8-figure commercial commitment from a top implant manufacturer. This gives them a proprietary data flywheel and distribution channel that pure-play AI companies and legacy planning tools cannot easily replicate, reinforced by $500K+ ARR achieved before Demo Day.
Funding History
- 2020 | Adrian Kilian and Jorge Padilla Pérez co-found Mango Medical in Freising, Germany.
- 2026 | Accepted into Y Combinator Winter 2026 batch (only company pursuing FDA approval for a MedTech product in the batch).
- 2026 | Secured 8-figure LOI from a leading orthopedic company.
- 2026 | Surpassed $500K ARR before Demo Day.
- 2026 | Pursuing FDA 510(k) clearance for shoulder arthroplasty planning.
Competitors
- Legacy Surgical Planning: Materialise (Mimics), Stryker (Blueprint 3D), Zimmer Biomet (Signature Solutions), Smith+Nephew (CORI).
- AI-Native Surgical Planning: Formus Labs (hip/knee AI planning), Bodycad (patient-specific implants + AI), Enhatch (AI surgical planning platform).
- Adjacent AI Medical Imaging: Imagen Technologies, Aidoc, Viz.ai (radiology AI, not orthopedic-specific).
